9 research outputs found
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom
Effects of primary biliary cholangitis on quality of life and health care costs in the United Kingdom
Background & Aims: There have been few high-quality studies of the costs, preference-based health-related quality of life (HRQoL) and cost effectiveness of treatments for primary biliary cholangitis (PBC). We aimed to estimate the marginal effects of PBC complications and symptoms, accounting for treatment, on HRQoL and the annual cost of health care in the United Kingdom (UK). These are essential components for evaluation of cost effectiveness and this information will aid in evaluation of new treatments. Methods: Questionnaires were mailed to 4583 participants in the UK-PBC research cohort and data were collected on HRQoL and use of the National Health Service (NHS) in the UK from 2015 through 2016. HRQoL was measured using the EQ-5D-5L instrument. The annual cost of resource use was calculated using unit costs obtained from NHS sources. We performed econometric analyses to determine the effects of treatment, symptoms, complications, liver transplantation status, and patient characteristics on HRQoL and annual costs. Results: In an analysis of data from 2240 participants (over 10% of all UK PBC patients), we found that PBC symptoms have a considerable effect on HRQoL. Ursodeoxycholic acid therapy was associated with significantly higher HRQoL regardless of response status. Having had a liver transplant and ascites were also independently associated with reduced HRQoL. Having had a liver transplant (US3401) were the factors with the two greatest mean annual costs to the NHS. Symptoms were not independently associated with cost but were associated with reduction in HRQoL for patients, indicating the lack of effective treatments for PBC symptoms. Conclusions: In an analysis of data from 2240 participants in the UK PBC, we found that HRQoL and cost estimates provide greater insight into the relative importance of PBC-related symptoms and complications. These findings provide estimates for health technology assessments of new treatments for PBC
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
BACKGROUND: Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted using pretreatment clinical parameters. METHODS: We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy. Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury and fibrosis, on liver biopsy samples. FINDINGS: 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response. In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for the score was 0·83 (95% CI 0·79-0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the UDCA response score was associated with ductular reaction (r=-0·556, p=0·0130) and intermediate hepatocytes (probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present). INTERPRETATION: We have derived and externally validated a model based on pretreatment variables that accurately predicts UDCA response. Association with histological features provides face validity. This model provides a basis to explore alternative approaches to treatment stratification in patients with primary biliary cholangitis. FUNDING: UK Medical Research Council and University of Milan-Bicocca
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Background Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin
treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after
12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk
can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted
using pretreatment clinical parameters.
Methods We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with
primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less
than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated
the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy.
Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury
and fibrosis, on liver biopsy samples.
Findings 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were
included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with
lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin
concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval
from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase
concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response.
In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with
follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for
the score was 0·83 (95% CI 0·79–0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the
UDCA response score was associated with ductular reaction (r=–0·556, p=0·0130) and intermediate hepatocytes
(probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present).
Interpretation We have derived and externally validated a model based on pretreatment variables that accurately
predicts UDCA response. Association with histological features provides face validity. This model provides a basis to
explore alternative approaches to treatment stratification in patients with primary biliary cholangitis
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Background Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin
treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after
12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk
can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted
using pretreatment clinical parameters.
Methods We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with
primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less
than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated
the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy.
Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury
and fibrosis, on liver biopsy samples.
Findings 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were
included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with
lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin
concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval
from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase
concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response.
In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with
follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for
the score was 0·83 (95% CI 0·79–0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the
UDCA response score was associated with ductular reaction (r=–0·556, p=0·0130) and intermediate hepatocytes
(probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present).
Interpretation We have derived and externally validated a model based on pretreatment variables that accurately
predicts UDCA response. Association with histological features provides face validity. This model provides a basis to
explore alternative approaches to treatment stratification in patients with primary biliary cholangitis
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Background Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin
treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after
12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk
can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted
using pretreatment clinical parameters.
Methods We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with
primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less
than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated
the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy.
Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury
and fibrosis, on liver biopsy samples.
Findings 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were
included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with
lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin
concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval
from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase
concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response.
In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with
follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for
the score was 0·83 (95% CI 0·79–0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the
UDCA response score was associated with ductular reaction (r=–0·556, p=0·0130) and intermediate hepatocytes
(probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present).
Interpretation We have derived and externally validated a model based on pretreatment variables that accurately
predicts UDCA response. Association with histological features provides face validity. This model provides a basis to
explore alternative approaches to treatment stratification in patients with primary biliary cholangitis
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Background: Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted using pretreatment clinical parameters. Methods: We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy. Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury and fibrosis, on liver biopsy samples. Findings: 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response. In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for the score was 0·83 (95% CI 0·79–0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the UDCA response score was associated with ductular reaction (r=–0·556, p=0·0130) and intermediate hepatocytes (probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present). Interpretation: We have derived and externally validated a model based on pretreatment variables that accurately predicts UDCA response. Association with histological features provides face validity. This model provides a basis to explore alternative approaches to treatment stratification in patients with primary biliary cholangitis. Funding: UK Medical Research Council and University of Milan-Bicocca
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
BACKGROUND
Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted using pretreatment clinical parameters.
METHODS
We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy. Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury and fibrosis, on liver biopsy samples.
FINDINGS
2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response. In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for the score was 0·83 (95% CI 0·79-0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the UDCA response score was associated with ductular reaction (r=-0·556, p=0·0130) and intermediate hepatocytes (probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present).
INTERPRETATION
We have derived and externally validated a model based on pretreatment variables that accurately predicts UDCA response. Association with histological features provides face validity. This model provides a basis to explore alternative approaches to treatment stratification in patients with primary biliary cholangitis.
FUNDING
UK Medical Research Council and University of Milan-Bicocca
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
BACKGROUND: Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted using pretreatment clinical parameters. METHODS: We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy. Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury and fibrosis, on liver biopsy samples. FINDINGS: 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response. In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for the score was 0·83 (95% CI 0·79-0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the UDCA response score was associated with ductular reaction (r=-0·556, p=0·0130) and intermediate hepatocytes (probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present). INTERPRETATION: We have derived and externally validated a model based on pretreatment variables that accurately predicts UDCA response. Association with histological features provides face validity. This model provides a basis to explore alternative approaches to treatment stratification in patients with primary biliary cholangitis. FUNDING: UK Medical Research Council and University of Milan-Bicocca